Jeffrey D Laskin Selected Research

Cholinergic Agents (Cholinergics)

12/2015	Ethynylphenyl carbonates and carbamates as dual-action acetylcholinesterase inhibitors and anti-inflammatory agents.
10/2015	Vitamin K3 (menadione) redox cycling inhibits cytochrome P450-mediated metabolism and inhibits parathion intoxication.
2/2012	Investigation of anticholinergic and non-steroidal anti-inflammatory prodrugs which reduce chemically induced skin inflammation.
5/2010	Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey D Laskin Research Topics

Disease

52	Inflammation (Inflammations) 05/2024 - 04/2002
39	Lung Injury 05/2024 - 04/2002
15	Fibrosis (Cirrhosis) 05/2023 - 12/2012
15	Edema (Dropsy) 01/2023 - 12/2010
13	Wounds and Injuries (Trauma) 03/2024 - 02/2012
12	Acute Lung Injury 05/2024 - 08/2014
12	Necrosis 09/2018 - 04/2002
10	Endotoxemia 05/2024 - 01/2002
8	Hyperplasia 05/2024 - 04/2002
8	Pneumonia (Pneumonitis) 05/2024 - 04/2002
6	Poisoning 02/2020 - 02/2011
5	Pulmonary Fibrosis (Fibrosing Alveolitis) 12/2020 - 03/2007
4	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 05/2024 - 02/2011
4	Neoplasms (Cancer) 10/2020 - 03/2008
4	Skin Diseases (Skin Disease) 01/2019 - 11/2002
4	Lung Diseases (Lung Disease) 12/2017 - 05/2002
3	Chronic Disease (Chronic Diseases) 04/2024 - 01/2019
3	Breast Neoplasms (Breast Cancer) 01/2019 - 08/2011
2	Dyslipidemias (Dyslipidemia) 01/2023 - 10/2020
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2023 - 03/2005
2	Corneal Injuries 10/2022 - 04/2016
2	Ataxia Telangiectasia (Louis Bar Syndrome) 06/2020 - 01/2019
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2019 - 12/2017
2	Asthma (Bronchial Asthma) 01/2019 - 12/2017
2	Vitiligo 08/2018 - 01/2018
2	Psoriasis (Pustulosis Palmaris et Plantaris) 08/2018 - 01/2018
2	Carcinogenesis 07/2014 - 10/2005
2	Bronchiolitis 06/2013 - 01/2011
1	Sepsis (Septicemia) 05/2024
1	Hemorrhage 03/2024
1	Burns 01/2023

Drug/Important Bio-Agent (IBA)

28	Irritants (Vesicants)IBA 04/2024 - 06/2010
23	Mechlorethamine (Nitrogen Mustard)FDA Link 04/2024 - 01/2011
20	Mustard Gas (Sulfur Mustard)IBA 10/2022 - 06/2010
18	OzoneIBA 05/2024 - 04/2002
14	Proteins (Proteins, Gene)FDA Link 03/2024 - 04/2002
10	Alkylating AgentsIBA 01/2021 - 10/2011
10	Acetaminophen (Paracetamol)FDA LinkGeneric 07/2012 - 10/2002
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2023 - 10/2002
6	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2012 - 04/2002
6	Transaminases (Aminotransferases)IBA 07/2012 - 11/2003
5	EnzymesIBA 05/2021 - 03/2008
5	DNA (Deoxyribonucleic Acid)IBA 06/2020 - 10/2007
5	2-chloroethyl ethyl sulfideIBA 04/2016 - 12/2010
5	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 03/2015 - 04/2002
5	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2011 - 04/2002
4	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 05/2024 - 10/2013
4	Reactive Nitrogen SpeciesIBA 01/2019 - 08/2010
4	Cholinergic Agents (Cholinergics)IBA 12/2015 - 05/2010
3	FibrinIBA 03/2024 - 12/2012
3	LipidsIBA 05/2023 - 12/2019
3	LipopolysaccharidesIBA 02/2023 - 01/2002
3	Surface-Active Agents (Surfactants)IBA 01/2023 - 09/2012
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 10/2021 - 10/2011
3	CatalaseIBA 05/2021 - 06/2003
3	Messenger RNA (mRNA)IBA 01/2021 - 11/2002
3	Laminin (Merosin)IBA 01/2020 - 04/2013
3	Peptide Hydrolases (Proteases)FDA Link 01/2019 - 05/2002
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 03/2004
3	Connective Tissue Growth FactorIBA 01/2019 - 01/2011
3	ProdrugsIBA 09/2018 - 02/2012
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 03/2016 - 10/2010
3	NitrogenIBA 01/2016 - 05/2002
3	Galectin 3 (LGALS3)IBA 04/2015 - 09/2012
3	EicosanoidsIBA 06/2010 - 04/2002
3	Peroxynitrous Acid (Peroxynitrite)IBA 03/2008 - 08/2004
3	NF-kappa B (NF-kB)IBA 10/2007 - 03/2002
2	Immunoglobulin M (IgM)IBA 05/2024 - 01/2023
2	Phospholipids (Phosphatides)FDA LinkGeneric 05/2024 - 11/2018
2	EndotoxinsIBA 05/2024 - 01/2020
2	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 03/2024 - 08/2014
2	Fibrinogen (Factor I)FDA Link 01/2023 - 10/2021
2	ChlorineIBA 01/2023 - 11/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2021 - 01/2019
2	CollagenIBA 12/2020 - 02/2005
2	LigandsIBA 10/2020 - 10/2002
2	DNA-Activated Protein KinaseIBA 06/2020 - 01/2019
2	AcetylcholinesteraseIBA 09/2018 - 01/2016
2	Sulfides (Thioethers)IBA 09/2018 - 10/2014
2	Indomethacin (Indometacin)FDA LinkGeneric 09/2018 - 01/2016
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 09/2018 - 01/2016
2	Photosensitizing Agents (Photosensitizers)IBA 08/2018 - 01/2018
2	QuinonesIBA 01/2017 - 08/2011
2	Oxygen (Dioxygen)IBA 01/2016 - 05/2002
2	Cholinergic Antagonists (Anticholinergics)IBA 01/2016 - 02/2012
2	Parathion (Ethyl Parathion)IBA 01/2016 - 10/2015
2	Protein CIBA 08/2014 - 09/2012
2	LipocalinsIBA 08/2014 - 10/2007
2	Toll-Like Receptor 4IBA 02/2013 - 12/2007
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2012 - 05/2010
1	Receptor for Advanced Glycation End ProductsIBA 05/2024
1	AlbuminsIBA 05/2024
1	N-(3-pyridylmethyl)adriamycin (YM 1)IBA 03/2024
1	Acetylcysteine (Siran)FDA LinkGeneric 03/2024
1	Hydroxyproline (4 Hydroxyproline)IBA 05/2023
1	Phosphates (Orthophosphate)IBA 05/2023
1	C.I. direct red 80IBA 05/2023
1	obeticholic acidIBA 05/2023
1	AerosolsIBA 01/2023

Therapy/Procedure

8	Therapeutics 05/2023 - 01/2011